acquired
Stage
1
Investors
About
VelosBio is a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). Its lead investigational candidate is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1.
Explore VelosBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.